Evidence profile
BPC-157 (10 mg Vial)
BPC-157 research includes experimental models and registered human studies. Published findings, trial registrations and untested uses should be distinguished.
01
Product identity
The actual material and formulation need to match any study used to interpret its effects.
02
What has been studied
Trial registry
The older oral study record
- Population or model
- Healthy volunteers
- Study route or material
- Oral tablet
The older safety/pharmacokinetics registration describes oral tablets. Its current status is unknown and no results are posted. It cannot establish a subcutaneous schedule.[1]
Trial registry
The newer injury study record
- Population or model
- Adults with MRI-confirmed acute hamstring injury
- Study route or material
- Subcutaneous, administered by study staff
A recruiting study record concerns acute hamstring injury with standardized rehabilitation and administration by study staff. No results were posted at the check date.[2]
03
Evidence limits
The reviewed registry records do not establish clinical benefit or a general-purpose treatment schedule.
Evidence from an animal experiment or another route cannot fill that gap.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
Exact product identity, strength and current stock-lot linkage.
Manufacturer-supported formulation, container, diluent compatibility and storage information.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[4]
05
Approval context
This profile has not established Canadian authorization of the linked research product.[3]
06
Available lab report
Sample report · 2026-08-14
BPC-063
COA-2026-SC-00978 · Peptide Test Canada; analysis credited to SideChain Analytics.[6]
Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
| Measurement | Reported result |
|---|---|
| Labelled total | 10 mg |
| Measured net total | 10.88 mg |
| Chromatographic purity | 99.6% |
Chromatographic purity and net peptide content are separate measurements. The report applies to this sample; its relationship to the current inventory lot has not been established. These results do not establish sterility, endotoxin compliance or suitability for clinical use.
07
Sources and review scope
- BPC-157 oral safety/pharmacokinetics registrationTrial registry · Fresh official ClinicalTrials.gov API status, intervention and results-posting record · Checked 2026-09-09
- BPC-157 acute hamstring injury trial registrationTrial registry · Fresh official ClinicalTrials.gov API status, intervention and results-posting record · Checked 2026-09-09
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: BPC-157 | 10mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
- Sample BPC-063: COA-2026-SC-00978Supplier-linked analytical sample report · Complete PDF and issuer check carried from same-day catalogue audit; current issuer status refreshed where recorded · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.